JP2015535282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535282A5 JP2015535282A5 JP2015540700A JP2015540700A JP2015535282A5 JP 2015535282 A5 JP2015535282 A5 JP 2015535282A5 JP 2015540700 A JP2015540700 A JP 2015540700A JP 2015540700 A JP2015540700 A JP 2015540700A JP 2015535282 A5 JP2015535282 A5 JP 2015535282A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- sprm
- composition
- administration
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 26
- 239000002379 progesterone receptor modulator Substances 0.000 claims description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 12
- 230000002354 daily effect Effects 0.000 claims description 12
- 201000009273 Endometriosis Diseases 0.000 claims description 8
- 230000027758 ovulation cycle Effects 0.000 claims description 6
- 239000000186 progesterone Substances 0.000 claims description 6
- 229960003387 progesterone Drugs 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 5
- 201000010260 leiomyoma Diseases 0.000 claims description 5
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical group C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 208000005641 Adenomyosis Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 3
- 230000005906 menstruation Effects 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 239000000227 bioadhesive Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 102000003998 progesterone receptors Human genes 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722095P | 2012-11-02 | 2012-11-02 | |
| US61/722,095 | 2012-11-02 | ||
| PCT/US2013/066095 WO2014070517A1 (en) | 2012-11-02 | 2013-10-22 | Methods and compositions for treating progesterone-dependent conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018010276A Division JP2018062530A (ja) | 2012-11-02 | 2018-01-25 | プロゲステロン依存性病態を処置する方法およびその組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535282A JP2015535282A (ja) | 2015-12-10 |
| JP2015535282A5 true JP2015535282A5 (enExample) | 2016-09-29 |
| JP6343619B2 JP6343619B2 (ja) | 2018-06-13 |
Family
ID=49510593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540700A Expired - Fee Related JP6343619B2 (ja) | 2012-11-02 | 2013-10-22 | プロゲステロン依存性病態を処置する方法およびその組成物 |
| JP2018010276A Withdrawn JP2018062530A (ja) | 2012-11-02 | 2018-01-25 | プロゲステロン依存性病態を処置する方法およびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018010276A Withdrawn JP2018062530A (ja) | 2012-11-02 | 2018-01-25 | プロゲステロン依存性病態を処置する方法およびその組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9545411B2 (enExample) |
| EP (1) | EP2914268B1 (enExample) |
| JP (2) | JP6343619B2 (enExample) |
| CN (1) | CN104755087A (enExample) |
| AU (1) | AU2013338305B2 (enExample) |
| CA (1) | CA2888377C (enExample) |
| ES (1) | ES2688821T3 (enExample) |
| HK (1) | HK1211852A1 (enExample) |
| IL (1) | IL238403B (enExample) |
| MX (1) | MX2015004821A (enExample) |
| WO (1) | WO2014070517A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986064A1 (en) * | 2015-05-18 | 2016-11-24 | Bayer Pharma Aktiengesellschaft | Selective progesterone receptor modulator (sprm) regimen |
| WO2017123577A1 (en) * | 2016-01-12 | 2017-07-20 | Repros Therapeutics Inc. | Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions |
| AU2020228299A1 (en) | 2019-02-28 | 2021-09-09 | Janssen Biotech, Inc. | Anti-IL-alpha antibody for the treatment of hidradenitis suppurativa |
| CA3179228A1 (en) | 2020-04-16 | 2021-10-21 | Janssen Biotech, Inc. | Treatment of hidradenitis suppurativa |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| CA2186953C (en) | 1995-02-02 | 2009-11-10 | Kristof Chwalsz | Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding |
| DE69702450T2 (de) | 1996-05-01 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | 21-substituierte progesteron derivate als antigestagene |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| WO1998008471A1 (en) | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
| US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
| AU2001245849B2 (en) | 2000-03-17 | 2007-01-04 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| IN191020B (enExample) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CZ299942B6 (cs) | 2000-10-18 | 2008-12-29 | Schering Aktiengesellschaft | Farmaceutické prostredky obsahující antiprogestinpro prevenci a lécení hormonálne závislých onemocnení |
| ES2312593T3 (es) | 2001-07-09 | 2009-03-01 | Repros Therapeutics Inc. | Procedimientos y materiales para el tratamiento de la deficiencia de testosterona en hombres. |
| EP1620060B1 (en) | 2003-04-29 | 2010-03-24 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| CN101080205B (zh) | 2004-07-09 | 2011-10-12 | 人口委员会股份有限公司 | 含孕酮受体调节剂的缓释组合物 |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| MX2007010659A (es) | 2005-03-22 | 2007-11-08 | Repros Therapeutics Inc | Regimenes de dosificacion para trans-clomifeno. |
| CA2604218A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| JP2009510127A (ja) | 2005-09-29 | 2009-03-12 | リプロス セラピューティクス インコーポレイテッド | ステロイド誘導体および多糖分解されたグリセリドを含む、向上したバイオアベイラビリティーを伴う処方物 |
| CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
| WO2007103510A2 (en) | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| PT3263112T (pt) | 2006-10-24 | 2020-08-25 | Allergan Pharmaceuticals Int Ltd | Composições e métodos para supressão de proliferações do endométrio |
| EP2144601A4 (en) | 2007-04-05 | 2012-10-10 | Univ Kansas | RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE |
| EP2148681B1 (en) | 2007-04-20 | 2016-03-16 | PregLem S.A. | Selective progesterone modulators in the treatment of uterine bleeding |
| WO2009037704A1 (en) | 2007-09-20 | 2009-03-26 | Bio-Pro Medical Ltd. | Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| EP2482914A1 (en) | 2009-09-29 | 2012-08-08 | Koninklijke Philips Electronics N.V. | Intrauterine electronic capsule for administering a substance |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| DE202011110355U1 (de) * | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-10-22 AU AU2013338305A patent/AU2013338305B2/en not_active Ceased
- 2013-10-22 EP EP13783818.1A patent/EP2914268B1/en active Active
- 2013-10-22 ES ES13783818.1T patent/ES2688821T3/es active Active
- 2013-10-22 HK HK15112776.8A patent/HK1211852A1/xx unknown
- 2013-10-22 JP JP2015540700A patent/JP6343619B2/ja not_active Expired - Fee Related
- 2013-10-22 MX MX2015004821A patent/MX2015004821A/es unknown
- 2013-10-22 CN CN201380057256.XA patent/CN104755087A/zh active Pending
- 2013-10-22 WO PCT/US2013/066095 patent/WO2014070517A1/en not_active Ceased
- 2013-10-22 US US14/440,023 patent/US9545411B2/en not_active Expired - Fee Related
- 2013-10-22 CA CA2888377A patent/CA2888377C/en not_active Expired - Fee Related
-
2015
- 2015-04-21 IL IL238403A patent/IL238403B/en active IP Right Grant
-
2018
- 2018-01-25 JP JP2018010276A patent/JP2018062530A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022022264A5 (enExample) | ||
| RU2011146058A (ru) | Способ контрацепции, используемый по мере необходимости | |
| JP2013514984A5 (enExample) | ||
| FI3518933T4 (fi) | Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi | |
| JP2015535282A5 (enExample) | ||
| FI3634419T3 (fi) | Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi | |
| CN1652798A (zh) | 连续抑制硫酸酯酶的孕激素的激素替代疗法 | |
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| JP2015527360A5 (enExample) | ||
| CN1652797A (zh) | 连续使用抑制硫酸酯酶的孕激素的避孕给药方案 | |
| JP2014529584A5 (enExample) | ||
| JP2017514851A5 (enExample) | ||
| RU2019135630A (ru) | Кобитолимод для применения при лечении воспалительного заболевания кишечника | |
| EA201792524A1 (ru) | Режим приема селективного модулятора рецептора прогестерона (sprm) | |
| EA201491614A1 (ru) | Способ лечения гинекологических заболеваний | |
| CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
| JP2013047269A5 (enExample) | ||
| US9795617B2 (en) | Hormone delivery system and method | |
| CN1771024A (zh) | 延长的经皮避孕方案 | |
| Maree et al. | Appendiceal perforation caused by an intrauterine contraceptive device: A case report | |
| JP2017502989A5 (enExample) | ||
| Sharma et al. | Centchroman regress mastalgia and fibroadenoma: An institutional study | |
| CN103800299A (zh) | 一种醋酸甲羟孕酮片及其制备工艺 | |
| TW200902028A (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases | |
| Pant et al. | Luteal Phase Defect (LPD): A necessary tool in assisted reproductive techniques |